1. Home
  2. MESO vs APLD Comparison

MESO vs APLD Comparison

Compare MESO & APLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • APLD
  • Stock Information
  • Founded
  • MESO 2004
  • APLD 2001
  • Country
  • MESO Australia
  • APLD United States
  • Employees
  • MESO N/A
  • APLD N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • APLD Investment Bankers/Brokers/Service
  • Sector
  • MESO Health Care
  • APLD Finance
  • Exchange
  • MESO Nasdaq
  • APLD Nasdaq
  • Market Cap
  • MESO 861.6M
  • APLD 1.2B
  • IPO Year
  • MESO N/A
  • APLD N/A
  • Fundamental
  • Price
  • MESO $9.93
  • APLD $7.95
  • Analyst Decision
  • MESO Strong Buy
  • APLD Strong Buy
  • Analyst Count
  • MESO 4
  • APLD 7
  • Target Price
  • MESO $11.50
  • APLD $11.29
  • AVG Volume (30 Days)
  • MESO 210.7K
  • APLD 13.4M
  • Earning Date
  • MESO 11-28-2024
  • APLD 10-09-2024
  • Dividend Yield
  • MESO N/A
  • APLD N/A
  • EPS Growth
  • MESO N/A
  • APLD N/A
  • EPS
  • MESO N/A
  • APLD N/A
  • Revenue
  • MESO $5,902,000.00
  • APLD $189,956,000.00
  • Revenue This Year
  • MESO $66.05
  • APLD $66.02
  • Revenue Next Year
  • MESO $348.27
  • APLD $49.29
  • P/E Ratio
  • MESO N/A
  • APLD N/A
  • Revenue Growth
  • MESO N/A
  • APLD 124.03
  • 52 Week Low
  • MESO $1.61
  • APLD $2.36
  • 52 Week High
  • MESO $11.05
  • APLD $8.79
  • Technical
  • Relative Strength Index (RSI)
  • MESO 64.16
  • APLD 59.06
  • Support Level
  • MESO $9.24
  • APLD $7.08
  • Resistance Level
  • MESO $10.39
  • APLD $8.28
  • Average True Range (ATR)
  • MESO 0.61
  • APLD 0.80
  • MACD
  • MESO 0.02
  • APLD -0.08
  • Stochastic Oscillator
  • MESO 66.06
  • APLD 64.82

About MESO Mesoblast Limited

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

About APLD Applied Digital Corporation

Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments; Data Center Hosting Business, Cloud Services Business, and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business which operates data centers to provide energized space to crypto mining customers.

Share on Social Networks: